299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
12 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04378153
(ClinicalTrials.gov)
August 25, 20204/5/2020Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator TherapyA Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)Cystic FibrosisOther: Discontinuation of hypertonic saline (HS);Other: Continuation of hypertonic saline (HS);Other: Discontinuation of dornase alfa (dnase);Other: Continuation of dornase alfa (dnase)David Nichols, MDCystic Fibrosis Foundation;Dartmouth-Hitchcock Medical Center;University of WashingtonRecruiting12 YearsN/AAll800N/AUnited States
2NCT01712334
(ClinicalTrials.gov)
December 201219/10/2012A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic FibrosisA Phase IV Multicenter, Randomized, Open Label, Two-Period, Crossover Study in Patients With Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the eRapid Nebulizer SystemCystic FibrosisDrug: dornase alfa [Pulmozyme®]Genentech, Inc.NULLCompleted6 YearsN/AAll99Phase 4United States
3NCT00680316
(ClinicalTrials.gov)
June 200816/5/2008A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic FibrosisA Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme® in 3- to 5-Year-Old Patients With Cystic FibrosisCystic FibrosisDrug: Dornase alfa;Drug: PlaceboGenentech, Inc.NULLTerminated3 Years5 YearsAll3Phase 4United States
4NCT00534079
(ClinicalTrials.gov)
September 200721/9/2007Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic RhinosinusitisNasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis - a Double Blind Placebo-controlled Cross-over, Bicenter, Prospective Clinical StudyCystic Fibrosis;RhinosinusitisDrug: Dornase alfa (Pulmozyme);Drug: isotonic salineUniversity of JenaNULLCompleted5 YearsN/ABoth23Phase 3Germany
5NCT00434278
(ClinicalTrials.gov)
March 200711/2/2007A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung DiseaseCystic FibrosisDrug: Dornase alfa;Drug: placeboGenentech, Inc.NULLTerminated14 YearsN/AAll27Phase 4United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00416182
(ClinicalTrials.gov)
December 200626/12/2006Nasally Delivered Pulmozyme for Sinusitis in Cystic FibrosisThe Use of Nasally Delivered Pulmozyme in the Treatment of Sinusitis in Cystic Fibrosis Patients: A Pilot StudySinusitis;Cystic FibrosisDrug: Pulmozyme (dornase alfa);Drug: PlaceboUniversity of VermontGenentech, Inc.Completed5 YearsN/AAll16Phase 2United States
7NCT00671723
(ClinicalTrials.gov)
October 200630/4/2008Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis PatientsDornase Alpha Versus Hypertonic Saline for Lung AtelectasisAtelectasisDrug: Normal saline:;Drug: Hypertonic Saline;Drug: Dornase alphaUniversity of OklahomaNULLCompleted18 Years90 YearsAll33N/AUnited States
8NCT00265434
(ClinicalTrials.gov)
December 200513/12/2005Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic RhinosinusitisNasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic RhinosinusitisCystic Fibrosis;Chronic RhinosinusitisDrug: PulmozymeUniversity of JenaPD Dr. Joachim Riethmöller, Tübingen;PD Dr. Assen Koitschev, Tübingen;Dr. Gerlind SchneiderCompleted5 YearsN/ABoth5Phase 3Germany
9NCT00117208
(ClinicalTrials.gov)
November 200530/6/2005Comparison of Inhaled Mannitol and rhDNase in Children With Cystic FibrosisA Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic FibrosisCystic FibrosisDrug: mannitol;Drug: mannitol + pulmozyme;Drug: Dornase alphaPharmaxisNULLCompleted8 Years18 YearsBoth20Phase 2United Kingdom
10EUCTR2015-003537-99-Outside-EU/EEA
(EUCTR)
05/07/2016A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic FibrosisA PHASE IV MULTICENTER, RANDOMIZED, OPEN LABEL, TWO-PERIOD CROSSOVER STUDY IN PATIENTS WITH CYSTIC FIBROSIS TO EVALUATE THE COMPARABLE EFFICACY AND SAFETY OF PULMOZYME® DELIVERED BY THE ERAPID™ NEBULIZER SYSTEM Cystic Fibrosis
MedDRA version: 19.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Trade Name: Pulmozyme
Product Name: Pulmozyme
INN or Proposed INN: DORNASE ALFA
F. Hoffmann-La Roche AGNULLNAFemale: yes
Male: yes
80Phase 4United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2007-001548-36-DE
(EUCTR)
27/07/2009Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler.- bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prospektive klinische Studie -Nasal Inhalation of Dornase alfa (Pulmozyme) in Patients with Cystic Fibrosis and Chronic Rhinosinusitis - pulmozyme-nasal-cfNasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler.- bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prospektive klinische Studie -Nasal Inhalation of Dornase alfa (Pulmozyme) in Patients with Cystic Fibrosis and Chronic Rhinosinusitis - pulmozyme-nasal-cf Cystic Fibrosis with chronic rhinosinusitisTrade Name: Pulmozyme
Product Name: Pulmozyme
INN or Proposed INN: Dornase alfa
Other descriptive name: recombiant human Desoxyribonuclease ( rhDNase)
University of JenaNULLNot RecruitingFemale: yes
Male: yes
16Phase 3Germany
12EUCTR2007-000935-25-NL
(EUCTR)
02/04/2007‘Peripheral targeting of inhaled rhDNase in stable CF patients.’‘Peripheral targeting of inhaled rhDNase in stable CF patients.’ Cystic Fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
MedDRA version: 9.1;Classification code 10011763;Term: Cystic fibrosis lung
Trade Name: Pulmozyme (Dornase alpha)
Product Name: Pulmozyme
ErasmusMC - Sophia Children's HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Netherlands